140 related articles for article (PubMed ID: 20609311)
1. Differential actions of eplerenone and spironolactone on the protective effect of testosterone against cardiomyocyte apoptosis in vitro.
Sánchez-Más J; Turpín MC; Lax A; Ruipérez JA; Valdés Chávarri M; Pascual-Figal DA
Rev Esp Cardiol; 2010 Jul; 63(7):779-87. PubMed ID: 20609311
[TBL] [Abstract][Full Text] [Related]
2. Non-genomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways?
Hermidorff MM; Faria Gde O; Amâncio Gde C; de Assis LV; Isoldi MC
Biochem Cell Biol; 2015 Feb; 93(1):83-93. PubMed ID: 25488178
[TBL] [Abstract][Full Text] [Related]
3. Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
Loan Le TY; Mardini M; Howell VM; Funder JW; Ashton AW; Mihailidou AS
Hypertension; 2012 Jun; 59(6):1164-9. PubMed ID: 22508833
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms.
De Silva DS; Wilson RM; Hutchinson C; Ip PC; Garcia AG; Lancel S; Ito M; Pimentel DR; Sam F
Am J Physiol Heart Circ Physiol; 2009 Jun; 296(6):H1983-93. PubMed ID: 19395558
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes.
Ramírez E; Klett-Mingo M; Ares-Carrasco S; Picatoste B; Ferrarini A; Rupérez FJ; Caro-Vadillo A; Barbas C; Egido J; Tuñón J; Lorenzo Ó
Cardiovasc Diabetol; 2013 Nov; 12():172. PubMed ID: 24261558
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of spironolactone on endothelial cell apoptosis.
Williams TA; Verhovez A; Milan A; Veglio F; Mulatero P
Endocrinology; 2006 May; 147(5):2496-505. PubMed ID: 16497808
[TBL] [Abstract][Full Text] [Related]
8. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Takeda Y
Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
[TBL] [Abstract][Full Text] [Related]
10. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
12. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
[TBL] [Abstract][Full Text] [Related]
13. Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.
Ye P; Yamashita T; Pollock DM; Sasano H; Rainey WE
Horm Metab Res; 2009 Jan; 41(1):35-9. PubMed ID: 18819053
[TBL] [Abstract][Full Text] [Related]
14. Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation.
Nakagawa H; Oberwinkler H; Nikolaev VO; Gaßner B; Umbenhauer S; Wagner H; Saito Y; Baba HA; Frantz S; Kuhn M
Circ Heart Fail; 2014 Sep; 7(5):814-21. PubMed ID: 25027872
[TBL] [Abstract][Full Text] [Related]
15. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
16. Eplerenone mimics features of the alternative activation in macrophages obtained from patients with heart failure and healthy volunteers.
Łabuzek K; Liber S; Bułdak Ł; Krupej-Kędzierska J; Machnik G; Bobrzyk M; Okopień B
Eur J Pharmacol; 2014 Mar; 726():96-108. PubMed ID: 24486397
[TBL] [Abstract][Full Text] [Related]
17. Mineralocorticoid receptor antagonists lead to increased adenosine bioavailability and modulate contractile cardiac parameters.
Hermidorff MM; de Assis LVM; Rodrigues JA; Soares LL; Andrade MHG; Natali AJ; Isoldi MC
Heart Vessels; 2020 May; 35(5):719-730. PubMed ID: 31820090
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist.
Arai K; Homma T; Morikawa Y; Ubukata N; Tsuruoka H; Aoki K; Ishikawa H; Mizuno M; Sada T
Eur J Pharmacol; 2015 Aug; 761():226-34. PubMed ID: 26073023
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia.
Mihailidou AS; Mardini M; Funder JW; Raison M
Hypertension; 2002 Aug; 40(2):124-9. PubMed ID: 12154101
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
Sica DA
Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
